Abstract: The present invention concerns a method for the in vitro diagnosis or prognosis of a graft tolerant or graft non-tolerant phenotype, comprising: determining from a grafted subject biological sample an expression profile comprising TMTC3 gene, optionally measuring other parameters, and determining the presence of a graft tolerant or graft non-tolerant phenotype from said expression profile and optional other parameters, wherein said method does not comprise determining an expression profile comprising, in addition to TMTC3, the following 7 genes: BUB1B, CDC2, CHEK1, MS4A1, RAB30, RHOH, and SYNGR3. Said method may further comprise, if said subject is diagnosed as a graft non-tolerant subject, diagnosing from the expression profile if said subject is developing chronic rejection. The present invention also relates to a medicament comprising a TMTC3 protein, or a fragment, an analogue or an analogue fragment thereof, in particular for the treatment, prevention, delay or inhibition of graft rejection.

Abstract: The present invention relates to a method of diagnosis and/or prognosis of an inflammatory condition, which method comprises determining the expression level of TRIB1 in a biological sample of a patient, in particular in peripheral blood or in a biopsy of a diseased tissue. Methods for treating inflammatory conditions by modulating TRIB1 expression or activity are also described.

Abstract: The method for analyzing the activation and motivation of T cells by analysis of T lymphocyte receptors of an organism consists in the following: determination of the number of transcripts for the gene V? in order to obtain first data; amplification of the region CDR3 of the T lymphocyte receptors for each of the V? genes associated with the organism; separation of the different lengths of the CDR3 of the T lymphocyte receptors for each of the V? genes associated with the organism and estimation of the proportion of transcripts of each length of the CDR3 in each V? family in order to obtain second data; representation of the first and second data according to the V? genes and the length of the regions CDR3 in a diagram with 4 variables.